Intranasal combo: fixed-dose combination of mometasone furoate and olopatadine hydrochloride in therapeutic strategies for rhinosinusitis

A novel strategy for the treatment of allergic rhinitis results from the innovative combination of antihistamine and intranasal corticosteroid drugs. By combining two preparations with different mechanism of action, this novel approach facilitates quick and effective controls of all upper respirator...

Full description

Saved in:
Bibliographic Details
Published inOtolaryngologia polska = The Polish otolaryngology Vol. 77; no. 6; p. 43
Main Authors Samoliński, Bolesław, Wojas, Oksana, Lipiec, Agnieszka, Krzych-Fałta, Edyta, Walkiewicz, Artur, Borowicz, Jacek, Samoliński, Krzysztof
Format Journal Article
LanguageEnglish
Published Poland 04.12.2023
Subjects
Administration, Intranasal
Adult
Anti-Allergic Agents - administration & dosage
Anti-Allergic Agents - therapeutic use
Drug Combinations
Female
Humans
Male
Middle Aged
Mometasone Furoate - administration & dosage
Mometasone Furoate - therapeutic use
Olopatadine Hydrochloride - administration & dosage
Olopatadine Hydrochloride - therapeutic use
Rhinitis, Allergic - drug therapy
Rhinosinusitis - drug therapy
Treatment Outcome
allergic rhinitis
olopatadine
ARIA
EPOS
mometasone
Online AccessGet more information

Cover

More Information
Summary:A novel strategy for the treatment of allergic rhinitis results from the innovative combination of antihistamine and intranasal corticosteroid drugs. By combining two preparations with different mechanism of action, this novel approach facilitates quick and effective controls of all upper respiratory tract allergy symptoms. The article presents the results of a study of olopatadine hydrochloride and mometasone furoate fixed-dose combination (GSP301) administered intranasally from a spray formulation, with an attempt at positioning the treatment within the ARIA and EPOS guidelines.
ISSN:2300-8423
DOI:10.5604/01.3001.0054.0941